Recruiting Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677 Conditions Carcinoma, FGFR Gene Alterations, FGFR Gene Amplification, +18 more Locations Urology Centers of Alabama — Homewood, Alabama, United States Arkansas Urology — Little Rock, Arkansas, United States Tri Valley Urology - Murrieta — Murrieta, California, United States Eisenhower Medical Associates — Rancho Mirage, California, United States View all 46 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations NCT06915753 Conditions Adenocarcinoma, Advanced Solid Tumors, Carcinoma, +26 more Locations USC Norris Comprehensive Cancer Center — Los Angeles, California, United States UCSF Medical Center at Mount Zion — San Francisco, California, United States Stanford Cancer Institute — Stanford, California, United States The University of Kansas Medical Center — Westwood, Kansas, United States View all 16 locations View more locations Show fewer locations Loading locations... View Trial Details
